Ann Pediatr Endocrinol Metab.  2020 Mar;25(1):15-23. 10.6065/apem.2020.25.1.15.

Bone health in pediatric patients with neurological disorders

• Ko A
• Kong J
• Samadov F
• Mukhamedov A
• Kim YM
• Lee YJ
• Nam SO

• KMID: 2501032
• DOI: http://doi.org/10.6065/apem.2020.25.1.15

Abstract

Patients with neurological disorders are at high risk of developing osteoporosis, as they possess multiple risk factors leading to low bone mineral density. Such factors include inactivity, decreased exposure to sunlight, poor nutrition, and the use of medication or treatment that can cause lower bone mineral density such as antiepileptic drugs, ketogenic diet, and glucocorticoids. In this article, mechanisms involved in altered bone health in children with neurological disorders and management for patients with epilepsy, cerebral palsy, and Duchenne muscular dystrophy regarding bone health are reviewed.

Keyword

Osteoporosis; Bone; Neurological disorders; Child; Epilepsy; Cerebral palsy

Figure

• 

  Fig. 1. Vitamin D, bone metabolism, and alteration in patients with neurological disorders. Boxed phrases refer to factors that can cause osteoporosis in patients with neurological disorders. * CYP450 enzyme-inducing drugs increase the metabolism of vitamin D resulting in decreased serum 25-hydroxyvitamin D level and subsequently decreased serum 1,25-dihydroxyvitamin D (1,25(OH)2D) level. † Ketogenic diet and other drugs that induce metabolic acidosis cause hypercalciuria in association with calcium loss from bone, resulting in negative calcium balance. Ketogenic diet can also cause inadequate calcium and vitamin D intake. ‡ Such a phenomenon is observed in a setting with normal serum calcium level. In the presence of low serum calcium level, 1,25(OH)2D induces bone resorption. AEDs, antiepileptic drugs.

Reference

References

1. Ward LM, Konji VN, Ma J. The management of osteoporosis in children. Osteoporos Int. 2016; 27:2147–79.

2. Houlihan CM, Stevenson RD. Bone density in cerebral palsy. Phys Med Rehabil Clin N Am. 2009; 20:493–508.

3. Bonjour JP, Theintz G, Buchs B, Slosman D, Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab. 1991; 73:555–63.

4. Melton LJ 3rd, Kan SH, Wahner HW, Riggs BL. Lifetime fracture risk: an approach to hip fracture risk assessment based on bone mineral density and age. J Clin Epidemiol. 1988; 41:985–94.

5. Henderson RC, Lark RK, Gurka MJ, Worley G, Fung EB, Conaway M, et al. Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics. 2002; 110(1 Pt 1):e5.

6. McNamara NA, Romanowski EMF, Olson DP, Shellhaas RA. Bone health and endocrine comorbidities in pediatric epilepsy. Semin Pediatr Neurol. 2017; 24:301–9.

7. Yasar E, Adiguzel E, Arslan M, Matthews DJ. Basics of bone metabolism and osteoporosis in common pediatric neuromuscular disabilities. Eur J Paediatr Neurol. 2018; 22:17–26.

8. Gordon CM, Leonard MB, Zemel BS. 2013 Pediatric Position Development Conference: executive summary and reflections. J Clin Densitom. 2014; 17:219–24.

9. Jones AR, Zacharin MR, Cameron FJ, Simm PJ. Bone density assessment in a tertiary paediatric centre over 13 years: referral patterns and limitations. J Paediatr Child Health. 2015; 51:608–13.

10. Frost HM. Bone's mechanostat: a 2003 update. Anat Rec A Discov Mol Cell Evol Biol. 2003; 275:1081–101.

11. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004; 80(6 Suppl):1689S–1696S.

12. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008; 122:398–417.

13. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96:1911–30.

14. Goltzman D. Functions of vitamin D in bone. Histochem Cell Biol. 2018; 149:305–12.

15. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011; 364:248–54.

16. Shellhaas RA, Joshi SM. Vitamin D and bone health among children with epilepsy. Pediatr Neurol. 2010; 42:385–93.

17. Mesias M, Seiquer I, Navarro MP. Calcium nutrition in adolescence. Crit Rev Food Sci Nutr. 2011; 51:195–209.

18. Blair HC, Robinson LJ, Huang CL, Sun L, Friedman PA, Schlesinger PH, et al. Calcium and bone disease. Biofactors. 2011; 37:159–67.

19. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011; 96:53–8.

20. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A. 2004; 101:7711–5.

21. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005; 16:713–6.

22. Soderpalm AC, Magnusson P, Ahlander AC, Karlsson J, Kroksmark AK, Tulinius M, et al. Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromuscul Disord. 2007; 17:919–28.

23. Francis RM, Anderson FH, Patel S, Sahota O, van Staa TP. Calcium and vitamin D in the prevention of osteoporotic fractures. Qjm. 2006; 99:355–63.

24. Kilpinen-Loisa P, Pihko H, Vesander U, Paganus A, Ritanen U, Makitie O. Insufficient energy and nutrient intake in children with motor disability. Acta Paediatr. 2009; 98:1329–33.

25. Mutlu GY, Kusdal Y, Ozsu E, Cizmecioglu FM, Hatun S. Prevention of Vitamin D deficiency in infancy: daily 400 IU vitamin D is sufficient. Int J Pediatr Endocrinol. 2011; 2011:4.

26. Gonzalez L, Nazario CM, Gonzalez MJ. Nutrition-related problems of pediatric patients with neuromuscular disorders. P R Health Sci J. 2000; 19:35–8.

27. Aydin K, Kartal A, Keles Alp E. High rates of malnutrition and epilepsy: two common comorbidities in children with cerebral palsy. Turk J Med Sci. 2019; 49:33–7.

28. Bailey DA, McCulloch RG. Bone tissue and physical activity. Can J Sport Sci. 1990; 15:229–39.

29. Frost HM, Schonau E. The "muscle-bone unit" in children and adolescents: a 2000 overview. J Pediatr Endocrinol Metab. 2000; 13:571–90.

30. Zacharin M. Current advances in bone health of disabled children. Curr Opin Pediatr. 2004; 16:545–51.

31. Mergler S, Evenhuis HM, Boot AM, De Man SA, Bindels-De Heus KG, Huijbers WA, et al. Epidemiology of low bone mineral density and fractures in children with severe cerebral palsy: a systematic review. Dev Med Child Neurol. 2009; 51:773–8.

32. Zacharin M. Assessing the skeleton in children and adolescents with disabilities: avoiding pitfalls, maximising outcomes. A guide for the general paediatrician. J Paediatr Child Health. 2009; 45:326–31.

33. Henderson RC. Bone density and other possible predictors of fracture risk in children and adolescents with spastic quadriplegia. Dev Med Child Neurol. 1997; 39:224–7.

34. Sturm PF, Alman BA, Christie BL. Femur fractures in institutionalized patients after hip spica immobilization. J Pediatr Orthop. 1993; 13:246–8.

35. Stasikelis PJ, Lee DD, Sullivan CM. Complications of osteotomies in severe cerebral palsy. J Pediatr Orthop. 1999; 19:207–10.

36. Henderson RC, Kemp GJ, Campion ER. Residual bonemineral density and muscle strength after fractures of the tibia or femur in children. J Bone Joint Surg Am. 1992; 74:211–8.

37. Wong J, Wirrell E. Physical activity in children/teens with epilepsy compared with that in their siblings without epilepsy. Epilepsia. 2006; 47:631–9.

38. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol. 2003; 15:454–7.

39. Verrotti A, Greco R, Morgese G, Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol. 2000; 47:385–8.

40. Nicholas JM, Ridsdale L, Richardson MP, Grieve AP, Gulliford MC. Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy: cohort study using the general practice research database. Seizure. 2013; 22:37–42.

41. Verrotti A, Coppola G, Parisi P, Mohn A, Chiarelli F. Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg. 2010; 112:1–10.

42. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia. 2004; 45:1330–7.

43. Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008; 118:69–86.

44. Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology. 2004; 62:2051–7.

45. Kulak CA, Borba VZ, Bilezikian JP, Silvado CE, Paola L, Boguszewski CL. Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs. Arq Neuropsiquiatr. 2004; 62:940–8.

46. Hosseinpour F, Ellfolk M, Norlin M, Wikvall K. Phenobarbital suppresses vitamin D3 25-hydroxylase expression: a potential new mechanism for drug-induced osteomalacia. Biochem Biophys Res Commun. 2007; 357:603–7.

47. Foss MC, Meneghelli UG, Tabosa Verissimo JM. The effect of the anticonvulsants phenobarbital and diphenylhydantoin on intestinal absorption of calcium. Acta Physiol Lat Am. 1979; 29:223–8.

48. Koch HU, Kraft D, von Herrath D, Schaefer K. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia. 1972; 13:829–34.

49. Luoma PV, Reunanen MI, Sotaniemi EA. Changes in serum triglyceride and cholesterol levels during longterm phenytoin treatment for epilepsy. Acta Med Scand. 1979; 206:229–31.

50. Harris M, Jenkins MV, Wills MR. Phenytoin inhibition of parathyroid hormone induced bone resorption in vitro. Br J Pharmacol. 1974; 50:405–8.

51. Hahn TJ, Scharp CR, Richardson CA, Halstead LR, Kahn AJ, Teitelbaum SL. Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro. J Clin Invest. 1978; 62:406–14.

52. Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology. 2008; 70:1586–93.

53. Valimaki MJ, Tiihonen M, Laitinen K, Tahtela R, Karkkainen M, Lamberg-Allardt C, et al. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res. 1994; 9:631–7.

54. Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA. Long-term anticonvulsant therapy leads to low bone mineral density--evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes. 2000; 108:37–43.

55. Takahashi A, Onodera K, Shinoda H, Mayanagi H. Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria. Jpn J Pharmacol. 2000; 82:82–4.

56. Ohta T, Wergedal JE, Gruber HE, Baylink DJ, Lau KH. Low dose phenytoin is an osteogenic agent in the rat. Calcif Tissue Int. 1995; 56:42–8.

57. Vernillo AT, Rifkin BR, Hauschka PV. Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone. 1990; 11:309–12.

58. von Borstel Smith M, Crofoot K, Rodriguez-Proteau R, Filtz TM. Effects of phenytoin and carbamazepine on calcium transport in Caco-2 cells. Toxicol In Vitro. 2007; 21:855–62.

59. Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology. 2001; 57:445–9.

60. Tekgul H, Serdaroglu G, Huseyinov A, Gokben S. Bone mineral status in pediatric outpatients on antiepileptic drug monotherapy. J Child Neurol. 2006; 21:411–4.

61. Tsukahara H, Kimura K, Todoroki Y, Ohshima Y, Hiraoka M, Shigematsu Y, et al. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int. 2002; 44:247–53.

62. Babayigit A, Dirik E, Bober E, Cakmakci H. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol. 2006; 35:177–81.

63. Andress DL, Ozuna J, Tirschwell D, Grande L, Johnson M, Jacobson AF, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol. 2002; 59:781–6.

64. Pack AM, Morrell MJ, Marcus R, Holloway L, Flaster E, Done S, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol. 2005; 57:252–7.

65. Kim SH, Lee JW, Choi KG, Chung HW, Lee HW. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav. 2007; 10:291–5.

66. Nicolaidou P, Georgouli H, Kotsalis H, Matsinos Y, Papadopoulou A, Fretzayas A, et al. Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study. J Child Neurol. 2006; 21:205–9.

67. Boluk A, Guzelipek M, Savli H, Temel I, Ozisik HI, Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res. 2004; 50:93–7.

68. Kumandas S, Koklu E, Gumus H, Koklu S, Kurtoglu S, Karakukcu M, et al. Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3. J Pediatr Endocrinol Metab. 2006; 19:529–34.

69. Rieger-Wettengl G, Tutlewski B, Stabrey A, Rauch F, Herkenrath P, Schauseil-Zipf U, et al. Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine. Pediatrics. 2001; 108:E107.

70. Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia. 2001; 42:1141–7.

71. Kafali G, Erselcan T, Tanzer F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr (Phila). 1999; 38:93–8.

72. Erbayat Altay E, Serdaroglu A, Tumer L, Gucuyener K, Hasanoglu A. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab. 2000; 13:933–9.

73. Voudris K, Moustaki M, Zeis PM, Dimou S, Vagiakou E, Tsagris B, et al. Alkaline phosphatase and its isoenzyme activity for the evaluation of bone metabolism in children receiving anticonvulsant monotherapy. Seizure. 2002; 11:377–80.

74. Oner N, Kaya M, Karasalihoglu S, Karaca H, Celtik C, Tutunculer F. Bone mineral metabolism changes in epileptic children receiving valproic acid. J Paediatr Child Health. 2004; 40:470–3.

75. Akin R, Okutan V, Sarici U, Altunbas A, Gokcay E. Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr Neurol. 1998; 19:129–31.

76. Simm PJ, Bicknell-Royle J, Lawrie J, Nation J, Draffin K, Stewart KG, et al. The effect of the ketogenic diet on the developing skeleton. Epilepsy Res. 2017; 136:62–6.

77. Schuh L, Barkley GL, Gates JR. Antiepileptic drugs and reduced bone mineral density. Epilepsy Behav. 2004; 5:296–300.

78. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology. 2002; 58:1348–53.

79. Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, et al. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy-antiepileptic drug and osteoporosis prevention trial. Epilepsia. 2013; 54:1997–2004.

80. Gniatkowska-Nowakowska A. Fractures in epilepsy children. Seizure. 2010; 19:324–5.

81. Valmadrid C, Voorhees C, Litt B, Schneyer CR. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol. 2001; 58:1369–74.

82. Fewtrell MS. Bone densitometry in children assessed by dual x ray absorptiometry: uses and pitfalls. Arch Dis Child. 2003; 88:795–8.

83. Kossoff EH, Zupec-Kania BA, Auvin S, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018; 3:175–92.

84. Leet AI, Mesfin A, Pichard C, Launay F, Brintzenhofeszoc K, Levey EB, et al. Fractures in children with cerebral palsy. J Pediatr Orthop. 2006; 26:624–7.

85. Stallings VA, Cronk CE, Zemel BS, Charney EB. Body composition in children with spastic quadriplegic cerebral palsy. J Pediatr. 1995; 126:833–9.

86. Fehlings D, Switzer L, Agarwal P, Wong C, Sochett E, Stevenson R, et al. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: a systematic review. Dev Med Child Neurol. 2012; 54:106–16.

87. Ozel S, Switzer L, Macintosh A, Fehlings D. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update. Dev Med Child Neurol. 2016; 58:918–23.

88. Larson CM, Henderson RC. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop. 2000; 20:71–4.

89. McDonald DG, Kinali M, Gallagher AC, Mercuri E, Muntoni F, Roper H, et al. Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol. 2002; 44:695–8.

90. King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, et al. Orthopedic outcomes of longterm daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007; 68:1607–13.

91. Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018; 17:347–61.

92. Bianchi ML, Mazzanti A, Galbiati E, Saraifoger S, Dubini A, Cornelio F, et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int. 2003; 14:761–7.

93. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010; 9:77–93.

94. Ma J, McMillan HJ, Karaguzel G, Goodin C, Wasson J, Matzinger MA, et al. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. Osteoporos Int. 2017; 28:597–608.

95. Ferraris JR, Pasqualini T, Alonso G, Legal S, Sorroche P, Galich AM, et al. Effects of deflazacort vs. methylprednisone: a randomized study in kidney transplant patients. Pediatr Nephrol. 2007; 22:734–41.

96. Ferraris JR, Pasqualini T, Legal S, Sorroche P, Galich AM, Pennisi P, et al. Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation. The Deflazacort Study Group. Pediatr Nephrol. 2000; 14:682–8.

97. Loftus J, Allen R, Hesp R, David J, Reid DM, Wright DJ, et al. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort. Pediatrics. 1991; 88:428–36.

98. Singh A, Schaeffer EK, Reilly CW. Vertebral fractures in Duchenne muscular dystrophy patients managed with deflazacort. J Pediatr Orthop. 2018; 38:320–4.